Long‐term trends in hepatitis C prevalence, treatment uptake and liver‐related events in the Swiss HIV Cohort Study

Author:

Baumann Lukas1ORCID,Braun Dominique L.23,Cavassini Matthias4ORCID,Stoeckle Marcel5,Bernasconi Enos6,Schmid Patrick7,Calmy Alexandra8,Haerry David9,Béguelin Charles110,Fux Christoph A.11,Wandeler Gilles1ORCID,Surial Bernard1ORCID,Rauch Andri1

Affiliation:

1. Department of Infectious Diseases, Inselspital, Bern University Hospital University of Bern Bern Switzerland

2. Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich University of Zurich Zurich Switzerland

3. Institute of Medical Virology University of Zurich Zurich Switzerland

4. Division of Infectious Diseases, Lausanne University Hospital University of Lausanne Lausanne Switzerland

5. Division of Infectious Diseases and Hospital Epidemiology University of Basel Basel Switzerland

6. Division of Infectious Diseases, Ente Ospedaliero Cantonale, Lugano University of Geneva and University of Southern Switzerland Lugano Switzerland

7. Division of Infectious Diseases, Cantonal Hospital St. Gallen St. Gallen Switzerland

8. HIV/AIDS Unit, Division of Infectious Diseases Geneva University Hospitals Geneva Switzerland

9. Chair Positive Council Zurich Switzerland

10. Division of Infectious Diseases Regional Hospital Biel Biel Switzerland

11. Division of Infectious Diseases and Infection Prevention Cantonal Hospital Aarau Aarau Switzerland

Abstract

AbstractBackground and AimsTreatment for chronic hepatitis C virus (HCV) infections changed dramatically in the last decade. We assessed changes in the prevalence of replicating HCV infection, treatment uptake and liver‐related morbidity and mortality in persons with HIV (PWH) and hepatitis C in the Swiss HIV cohort study.MethodsWe included all cohort participants between 2002 and 2021. We assessed yearly prevalence of replicating HCV infection, overall and liver‐related mortality, as well as the yearly incidence of liver‐related events in persons with at least one documented positive HCV‐RNA.ResultsOf 14 652 participants under follow‐up, 2294 had at least one positive HCV‐RNA measurement. Of those, 1316 (57%) ever received an HCV treatment. Treatment uptake increased from 8.1% in 2002 to a maximum of 32.6% in 2016. Overall, prevalence of replicating HCV infection declined from 16.5% in 2004 to 1.3% in 2021. HCV prevalence declined from 63.2% to 7.1% in persons who inject drugs, and from 4.1% to 0.6% in men who have sex with men. Among the 2294 persons with replicating HCV infection, overall mortality declined from a maximum of 3.3 per 100 patient‐years (PY) to 1.1 per 100 PY, and incidence of liver‐related events decreased from 1.4/100 PY to 0.2/100 PY.ConclusionsThe introduction of DAA therapy was associated with a more than 10‐fold reduction in prevalence of replicating HCV infection in PWH, approaching the estimates in the general population. Overall mortality and liver‐related events declined substantially in persons living with HIV and hepatitis C.

Funder

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Publisher

Wiley

Subject

Hepatology

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3